Literature DB >> 15767223

Community-associated methicillin-resistant Staphylococcus aureus: a review.

Michael J Rybak1, Kerry L LaPlante.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a common bacterial pathogen responsible for a variety of infections in both children and adults. Treatment of infections caused by this organism is problematic due to its resistance to many drugs. Recent reports of community-associated MRSA (CA-MRSA) infections in patients with no known risk factors have serious public health implications. Therapeutic options for these infections are untested; therefore, the potential exists for high morbidity and mortality. Recently, clinical definitions have been established, and new molecular approaches have allowed investigators to distinguish CA-MRSA more easily from traditional nosocomial-derived MRSA strains. Identifying potential risk factors for CA-MRSA acquisition and fully characterizing the epidemiologic, clinical, and molecular properties of these strains are necessary to provide effective therapeutic guidelines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767223     DOI: 10.1592/phco.25.1.74.55620

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  25 in total

1.  Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.

Authors:  Joseph D'Ignazio; Marco A Camere; Drew E Lewis; Daniel Jorgensen; Jeanne D Breen
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Methicillin-resistant Staphylococcus aureus: from the hospital to the community.

Authors:  Armando Paez; Daniel Skiest
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

3.  Comparison of antibiotic resistance, virulence gene profiles, and pathogenicity of methicillin-resistant and methicillin-susceptible Staphylococcus aureus using a Caenorhabditis elegans infection model.

Authors:  Terissa Thompson; Paul D Brown
Journal:  Pathog Glob Health       Date:  2014-10-16       Impact factor: 2.894

4.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Hyaluronic acid binding peptides prevent experimental staphylococcal wound infection.

Authors:  Kathleen J Zaleski; Tadeusz Kolodka; Colette Cywes-Bentley; Rachel M McLoughlin; Mary L Delaney; Bernard T Charlton; Wendy Johnson; Arthur O Tzianabos
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

Review 6.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

7.  The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  B Y Lee; A Singh; M Z David; S M Bartsch; R B Slayton; S S Huang; S M Zimmer; M A Potter; C M Macal; D S Lauderdale; L G Miller; R S Daum
Journal:  Clin Microbiol Infect       Date:  2012-06-19       Impact factor: 8.067

8.  Analysis of Slovenian MRSA strains with susceptibility patterns suggestive of CA-MRSA.

Authors:  Irena Grmek-Kosnik; Urska Dermota; Helena Ribic; Mateja Ravnik; Martina Kavcic; Tatjana Harlander; Tjasa Zohar-Cretnik; Iztok Strumbelj; Ljudmila Sarjanovic; Alenka Kraigher
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

9.  Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.

Authors:  Kerry L LaPlante; Steven N Leonard; David R Andes; William A Craig; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

10.  ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba.

Authors:  Philippe Rs Lagacé-Wiens; Kim A Nichol; Lindsay E Nicolle; Mel R Decorby; Melissa McCracken; Michelle J Alfa; Michael R Mulvey; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.